Reduced Monocyte Subsets, Their HLA-DR Expressions, and Relations to Acute Phase Reactants in Severe COVID-19 Cases

Basit Öğe Kaydı
dc.contributor.authorCizmecioglu, Ahmet
dc.contributor.authorEmsen, Ayca
dc.contributor.authorSumer, Sua
dc.contributor.authorErgun, Dilek
dc.contributor.authorAkay Cizmecioglu, Hilal
dc.contributor.authorTurk Dagi, Hatice
dc.contributor.authorArtac, Hasibe
dc.date.accessioned2024-02-23T14:20:59Z
dc.date.available2024-02-23T14:20:59Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractMonocytes are one of the principal immune defense cells that encounter infectious agents. However, an essential role of monocytes has been shown in the spread of viruses throughout the human body. Considering this dilemma, this study aimed to evaluate monocyte subsets and Human Leukocyte Antigen-DR isotype (HLA-DR) expressions in clinical coronavirus disease 2019 (COVID-19) cases. This prospective, multicenter, case-control study was conducted with COVID-19 patients and healthy controls. The patient group was divided into two subgroups according to disease severity (severe and non-severe). Three monocyte subsets (classical, CL; intermediate, INT; non-classical, NC) were analyzed with flow cytometry upon the patients' hospital admission. A total of 42 patients with COVID-19 and 30 controls participated in this study. The patients' conditions were either severe (n = 23) or non-severe (n = 19). All patients' monocyte and HLA-DR expressions were decreased compared with the controls (p < 0.05). Per disease severity, all monocyte subsets were not significant with disease severity; however, the HLA-DR expressions of CL monocytes (p = 0.002) and INT monocytes (p = 0.025) were more decreased in the severe patient group. In patients with various clinical features, NC monocytes were more affected. Based on these results, NC monocytes were more decreased in acute COVID-19 cases, though related various clinics decreased all monocyte subsets in these patients. Decreased monocyte HLA expressions may be a sign of immune suppression in severe patients, even when the percentage of monocyte levels has not decreased yet.en_US
dc.description.sponsorshipScientific Research ProjectFound of Selcuk University under Grant [19611034]en_US
dc.description.sponsorshipThis work was supported by the Scientific Research ProjectFound of Selcuk University under Grant (no. 19611034).en_US
dc.identifier.doi10.1089/vim.2021.0196
dc.identifier.endpage282en_US
dc.identifier.issn0882-8245
dc.identifier.issn1557-8976
dc.identifier.issue3en_US
dc.identifier.pmid35196160en_US
dc.identifier.scopus2-s2.0-85129648604en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.1089/vim.2021.0196
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13394
dc.identifier.volume35en_US
dc.identifier.wosWOS:000760738600001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofViral Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCovid-19en_US
dc.subjectDisease Severityen_US
dc.subjectHla-Dr Expressionsen_US
dc.subjectMonocyte Subsetsen_US
dc.titleReduced Monocyte Subsets, Their HLA-DR Expressions, and Relations to Acute Phase Reactants in Severe COVID-19 Casesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu